Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractNeurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so-called multitarget-directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer's disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.
CitationBiomed Res Int. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
JournalBioMed research international
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
- Authors: Minarini A, Milelli A, Tumiatti V, Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Motori E, Angeloni C, Hrelia S
- Issue date: 2012 Feb
- Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core.
- Authors: Lin H, Li Q, Gu K, Zhu J, Jiang X, Chen Y, Sun H
- Issue date: 2017
- The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
- Authors: Mesiti F, Chavarria D, Gaspar A, Alcaro S, Borges F
- Issue date: 2019 Nov 1
- Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
- Authors: Ramos E, Egea J, de Los Ríos C, Marco-Contelles J, Romero A
- Issue date: 2017 May
- Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease.
- Authors: Wenzel TJ, Klegeris A
- Issue date: 2018 Aug 15